Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTAI NASDAQ:ETON NASDAQ:IOBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.13$1.23$1.01▼$8.08$34.89M0.31629,650 shs348,912 shsETONEton Pharmaceuticals$32.59$25.81$13.09▼$35.66$892.64M0.82421,508 shs523,701 shsIOBTIO Biotech$0.05$0.08$0.03▼$2.79$3.45M0.887.09 million shsN/A10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics0.00%-0.88%+6.60%-30.67%-18.71%ETONEton Pharmaceuticals0.00%+7.70%+41.57%+78.28%+64.51%IOBTIO Biotech0.00%0.00%0.00%-85.79%-96.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.13$1.23$1.01▼$8.08$34.89M0.31629,650 shs348,912 shsETONEton Pharmaceuticals$32.59$25.81$13.09▼$35.66$892.64M0.82421,508 shs523,701 shsIOBTIO Biotech$0.05$0.08$0.03▼$2.79$3.45M0.887.09 million shsN/A10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics0.00%-0.88%+6.60%-30.67%-18.71%ETONEton Pharmaceuticals0.00%+7.70%+41.57%+78.28%+64.51%IOBTIO Biotech0.00%0.00%0.00%-85.79%-96.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTAIBioXcel Therapeutics 2.25Hold$11.00873.45% UpsideETONEton Pharmaceuticals 2.40Hold$41.0025.81% UpsideIOBTIO Biotech 1.60Reduce$3.507,191.67% UpsideCurrent Analyst Ratings BreakdownLatest IOBT, BTAI, and ETON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ETONEton Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $57.004/21/2026ETONEton Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026BTAIBioXcel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026ETONEton Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/2/2026BTAIBioXcel Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $5.003/27/2026IOBTIO Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/20/2026ETONEton Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$37.00 ➝ $52.003/20/2026ETONEton Pharmaceuticals B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$26.00 ➝ $31.003/20/2026ETONEton Pharmaceuticals Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $35.003/19/2026ETONEton Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/17/2026BTAIBioXcel Therapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$17.00(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTAIBioXcel Therapeutics$640K54.52N/AN/A($3.42) per share-0.33ETONEton Pharmaceuticals$79.95M11.16$0.01 per share6,287.62$1.12 per share29.10IOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTAIBioXcel Therapeutics-$69.90M-$5.75N/AN/AN/A-11,078.53%N/A-201.53%8/11/2026 (Estimated)ETONEton Pharmaceuticals-$4.60M-$0.07N/A17.91N/A-1.70%-5.68%-1.49%8/6/2026 (Estimated)IOBTIO Biotech-$95.49M-$1.35N/AN/AN/AN/A-517.22%-200.69%N/ALatest IOBT, BTAI, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026BTAIBioXcel Therapeutics-$0.5325-$0.54-$0.0075-$0.54$0.38 million$0.21 million5/14/2026Q1 2026ETONEton Pharmaceuticals$0.10$0.05-$0.05$0.05$22.31 million$24.27 million3/27/2026Q4 2025BTAIBioXcel Therapeutics-$0.58-$0.58N/A$0.65$0.15 millionN/A3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTAIBioXcel TherapeuticsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTAIBioXcel TherapeuticsN/A0.620.82ETONEton Pharmaceuticals0.621.210.88IOBTIO Biotech18.292.012.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTAIBioXcel Therapeutics30.68%ETONEton Pharmaceuticals27.86%IOBTIO Biotech54.76%Insider OwnershipCompanyInsider OwnershipBTAIBioXcel Therapeutics3.70%ETONEton Pharmaceuticals16.49%IOBTIO Biotech2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTAIBioXcel Therapeutics9030.88 million29.74 millionNo DataETONEton Pharmaceuticals2027.39 million22.88 millionOptionableIOBTIO Biotech3071.95 million68.50 millionNot OptionableIOBT, BTAI, and ETON HeadlinesRecent News About These CompaniesIO Biotech: After Considering All Strategic Alternatives, Co. Ceased Operations and Filed aVoluntary Petition for Relief Under Provisions of Chapter 7 of Title 11 of U.S ...March 31, 2026 | marketwatch.comWhy Are Shares Of IO Biotech Plummeting?March 31, 2026 | benzinga.comHere's Why IO Biotech, Inc. (IOBT) Looks Ripe for Bottom FishingFebruary 13, 2026 | zacks.comIO Biotech (IOBT) price target decreased by 33.83% to 1.66February 4, 2026 | msn.comIO Biotech Engages Raymond James as Financial Advisor Amid Workforce Reduction and Cost-Containment MeasuresJanuary 30, 2026 | quiverquant.comQIO Biotech Provides Corporate UpdateJanuary 30, 2026 | globenewswire.comPiper Sandler downgrades IO Biotech (IOBT)January 27, 2026 | msn.comPiper downgrades IO Biotech amid strategic alternatives evaluationJanuary 27, 2026 | finance.yahoo.comIO Biotech stock tumbles after Piper Sandler downgrades on strategic reviewJanuary 26, 2026 | za.investing.comModerna cancer vaccine holds up; IO Biotech considers a saleJanuary 21, 2026 | biopharmadive.comBIO Biotech stock plummets after company explores strategic alternativesJanuary 21, 2026 | au.investing.comIO Biotech Announces Exploration of Strategic AlternativesJanuary 21, 2026 | globenewswire.comIO Biotech receives Nasdaq notice for bid price noncomplianceDecember 20, 2025 | msn.comIO Biotech publishes MM1636 trial results in Nature CommunicationsDecember 16, 2025 | msn.comIO Biotech Publishes Five-Year Results from MM1636 Trial Showing Potential of IO102-IO103 in Metastatic Melanoma TreatmentDecember 15, 2025 | quiverquant.comQIO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature CommunicationsDecember 15, 2025 | globenewswire.comIO Biotech Announces Participation in Upcoming December Investor ConferencesNovember 26, 2025 | globenewswire.comIO Biotech, Inc. (IOBT) Upgraded to Buy: Here's WhyNovember 19, 2025 | zacks.comIO Biotech, Inc. (NASDAQ:IOBT) Receives Average Rating of “Hold†from AnalystsNovember 19, 2025 | defenseworld.netDIO Biotech’s Q3 2025: Progress in Cancer Vaccine TrialsNovember 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIOBT, BTAI, and ETON Company DescriptionsBioXcel Therapeutics NASDAQ:BTAI$1.13 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.15 +0.02 (+1.42%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Eton Pharmaceuticals NASDAQ:ETON$32.59 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$33.15 +0.56 (+1.72%) As of 05/22/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.IO Biotech NASDAQ:IOBT$0.05 0.00 (0.00%) As of 04/7/2026IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
